AYTU BioPharma AYTU

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
-$0.01 (-0.78%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of AYTU BioPharma (AYTU)
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.

Key Insights

Critical company metrics and information

  • Latest Closing Price

    $1.25

  • Market Cap

    $7.71 Million

  • Price-Earnings Ratio

    -1.29

  • Total Outstanding Shares

    6.17 Million Shares

  • Total Employees

    102

  • Dividend

    No dividend

  • IPO Date

    February 15, 2008

  • SIC Description

    Pharmaceutical Preparations

  • Primary Exchange

    NASDAQ

  • Type

    Common Stock

  • Headquarters

    7900 e. union avenue, Denver, CO, 80237

  • Homepage

    https://www.aytubio.com

Historical Stock Splits

If you bought 960,000 shares of AYTU before July 1, 2016, you'd have 1 share today.
Execution DateSplit Amount
January 6, 20231-for-20 (Reverse Split)
December 9, 20201-for-10 (Reverse Split)
August 13, 20181-for-20 (Reverse Split)
August 29, 20171-for-20 (Reverse Split)
July 1, 20161-for-12 (Reverse Split)

Cash Flow Statement

January 1, 2024 to December 31, 2024
MetricValue
Net Cash Flow From Operating Activities$673,000
Net Cash Flow From Investing Activities, Continuing$447,000
Net Cash Flow From Operating Activities, Continuing$673,000
Net Cash Flow$869,000
Net Cash Flow From Financing Activities$-251,000
Net Cash Flow, Continuing$869,000

Income Statement

January 1, 2024 to December 31, 2024
MetricValue
Research and Development$2.61 Million
Income/Loss From Continuing Operations After Tax$2.14 Million
Revenues$68.76 Million
Net Income/Loss Attributable To Parent$2.26 Million
Net Income/Loss$2.26 Million
Net Income/Loss Available To Common Stockholders, Basic$2.26 Million

Comprehensive Income

January 1, 2024 to December 31, 2024
MetricValue
Comprehensive Income/Loss$2.26 Million
Other Comprehensive Income/Loss$0
Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
Comprehensive Income/Loss Attributable To Parent$2.26 Million

Balance Sheet

January 1, 2024 to December 31, 2024
MetricValue
Inventory$11.09 Million
Equity Attributable To Parent$30.77 Million
Current Assets$116.23 Million
Other Current Assets$98.97 Million
Other Current Liabilities$48.38 Million
Noncurrent Assets$53.17 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about AYTU from trusted financial sources
    All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

    ⓒ 2025 Financhle. All Rights Reserved.